Reslizumab
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Reslizumab: From Eosinophilic Asthma to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Reslizumab is a biologic (anti-IL-5 monoclonal antibody) known for use in severe eosinophilic asthma, though this original indication is not confirmed in the current evidence pack. The TxGNN model predicts it may be effective for Thrombocytopenia Due to Immune Destruction, but no clinical trials and no literature currently support this specific direction — the prediction is model-output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from regulatory license data (drug is not marketed in this jurisdiction); known drug-class use is eosinophilic asthma, per mechanistic narrative in the evidence pack rather than an official label |
| Predicted New Indication | Thrombocytopenia Due to Immune Destruction |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L5 (model prediction only, no clinical or preclinical support) |
| Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is officially marked as a data gap (DG002) in this evidence pack. However, the model’s own rationale text identifies reslizumab as an anti-IL-5 monoclonal antibody that suppresses eosinophil proliferation and activation, consistent with its known use in eosinophilic asthma.
Critically, the evidence pack’s own mechanistic assessment states that this pathway has no direct biological link to the core mechanism of immune thrombocytopenia (autoantibody-mediated platelet destruction and impaired megakaryopoiesis). The high TxGNN score (99.53%) is interpreted as likely reflecting indirect graph connections between eosinophil/immune-modulation nodes in the knowledge graph, rather than a causal or pharmacologically plausible relationship. No supporting clinical or translational evidence currently exists.
Given the absence of mechanistic plausibility and supporting evidence, this prediction should be treated as a low-confidence, purely data-driven signal rather than a scientifically supported repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No license or NDA records are available — the drug is not currently marketed in this jurisdiction, so no approved indication text can be extracted.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA-equivalent warnings/contraindications for this drug are marked as a blocking data gap — see Next Steps.)
Additional Predicted Indication (Secondary, Not Elaborated)
The evidence pack also includes a second, weaker candidate: Primary Release Disorder of Platelets (TxGNN score 99.25%, rank 16467, Evidence Level L5). The single supporting reference (PMID 20565230, a 2010 review on hypereosinophilic syndrome management) discusses a different anti-IL-5 antibody (mepolizumab) and does not specifically address platelet release disorders — it is class-level, indirect evidence at best. Recommendation for this candidate is also Hold.
Conclusion and Next Steps
Decision: Hold
Rationale: Both predicted indications are supported only by TxGNN model scores with no corroborating clinical trials or disease-specific literature, and the evidence pack’s own mechanistic analysis finds no credible biological pathway connecting reslizumab’s anti-IL-5 activity to immune-mediated platelet disorders. Evidence Level L5 and the absence of any experimental or clinical signal do not support advancing to further evaluation stages (currently S0).
To proceed, the following is needed:
- TFDA-equivalent warnings, contraindications, and label data (DG001 — blocking; required before any safety pre-screen/S1 stage)
- Confirmed mechanism of action via DrugBank API query (DG002 — high priority; needed to properly assess mechanistic plausibility)
- Disease-specific preclinical or translational evidence directly linking IL-5/eosinophil biology to immune thrombocytopenia or platelet release disorders, if this candidate is to be reconsidered
- Continued monitoring for new clinical trial registrations or publications specific to reslizumab in either predicted indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.